We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Sanofi | EU:SAN | Euronext | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.60 | -0.65% | 91.30 | 91.12 | 91.90 | 92.24 | 91.09 | 91.83 | 891,417 | 16:40:00 |
From May 2019 to May 2024
By Cristina Roca
Sanofi SA (SAN.FR) has struck a deal to acquire exclusive over-the-counter rights for Tamiflu in the U.S., it said Tuesday.
Under the agreement struck with Roche Holding AG (RO.EB), whose subsidiary Genentech currently sells Tamiflu for prescription use in the U.S., Sanofi will be responsible for leading negotiations with the Food and Drug Administration to switch Tamiflu to over-the-counter, and will fund all studies needed to support the switch, it said.
The French pharmaceutical company will also be responsible for marketing, scientific engagement and distribution of Tamiflu over the counter in the U.S.
Tamiflu is a medicine for the prevention and treatment of influenza or flu. The deal is part of Sanofi's global cough and cold strategy, the company said.
Roche will continue to market Tamiflu in the rest of the world, Sanofi said.
No financial details of the deal were disclosed.
Write to Cristina Roca at cristina.roca@dowjones.com; @_cristinaroca
(END) Dow Jones Newswires
July 23, 2019 01:32 ET (05:32 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
